Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia

Folia Medica Indonesiana · Vol. 59 No. 3 (2023) · hlm. 267–273

DOI
10.20473/fmi.v59i3.46944
ISSN
2355-8393, 2599-056X
Terbit
2023-09-10
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Highlights: 1. As there is a scarcity of publications on the use of metformin for COVID-19 in Indonesia, the findings of this present study may contribute more insight to the existing body of research and provide data specific to the Southeast Asian population.2. This study revealed a decreased mortality rate associated with metformin use in diabetic patients with mild to moderate COVID-19 infection.3. This study suggests that diabetic patients may continue metformin treatment during a COVID-19 infection as the medication has sustained therapeutic effects. Abstract COVID-19 patients with comorbidities, such as type 2 diabetes (T2DM), have a higher mortality rate compared to those without any comorbidities. T2DM patients usually receive metformin as their first-line treatment. However, the effectiveness of metformin in reducing mortality rates still requires further analysis. The objective of this study was to analyze the effectiveness of metformin in reducing mortality rates among COVID-19 patients with T2DM. An analytic observational design with a retrospective cohort approach was used in this study. Samples were acquired from hospitalized COVID-19 patients with T2DM medical records at Fatmawati Central General Hospital, Jakarta, Indonesia, throughout 2020–2021. The samples were collected using a purposive sampling technique and analyzed using Chi-square test (p<0.05; RR<1). This study comprised 137 samples, with 56 samples receiving metformin and 81 not receiving metformin. The mortality rate in the sample group that received metformin was lower (19.6%) compared to the group that was not given the medication (38.3%). The Chi-square test results indicated a statistically significant relationship between metformin treatment and a lower mortality rate among COVID-19-contracted individuals with T2DM (p=0.020; RR=0.513). Therefore, this study concludes that the administration of metformin treatment reduces mortality among COVID-19 patients with T2DM.

Kata kunci

Jaringan kolaborasi para penulis

17 penulis · 45 tautan kepenulisan bersama · 15 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Pembangunan Nasional Veteran Jakarta
  • Fatmawati Hospital
  • Griffith University
  • Yarsi University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Ibnu Malkan Bakhrul IlmiUniversitas Pembangunan Nasional Veteran Jakarta1
Avliya Quratul MarjanUniversitas Pembangunan Nasional Veteran Jakarta1
Utami WahyuningsihUniversitas Pembangunan Nasional Veteran Jakarta1
Amelia Luthfiyah MulyadewiUniversitas Pembangunan Nasional Veteran Jakarta1
Indra Darpa KusumaYarsi University1
Chika Nur FikrianaUniversitas Pembangunan Nasional Veteran Jakarta1
Riezky Valentina AstariUniversitas Pembangunan Nasional Veteran Jakarta1
Arman Yurisaldi SalehUniversitas Pembangunan Nasional Veteran Jakarta1
Annisa Azzahra RamadinaUniversitas Pembangunan Nasional Veteran Jakarta1
Tiwuk SusantiningsihUniversitas Pembangunan Nasional Veteran Jakarta1
Maria Selvester ThadeusUniversitas Pembangunan Nasional Veteran Jakarta1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia</dc:title><dc:creator>Yudivaniel Zihono</dc:creator><dc:creator>Hany Yusmaini</dc:creator><dc:creator>Uswatun Hasanah</dc:creator><dc:creator>Erna Harfiani</dc:creator><dc:creator>Md Ikhsan Mokoagow</dc:creator><dc:creator>Dicky Budiman</dc:creator><dc:subject>metformin</dc:subject><dc:subject>COVID-19 pandemic</dc:subject><dc:subject>type 2 diabetes</dc:subject><dc:subject>mortality</dc:subject><dc:subject>comorbidities</dc:subject><dc:subject>hospitalized patients</dc:subject><dc:subject>drug effectiveness</dc:subject><dc:description xml:lang="en">Highlights: 1. As there is a scarcity of publications on the use of metformin for COVID-19 in Indonesia, the findings of this present study may contribute more insight to the existing body of research and provide data specific to the Southeast Asian population.2. This study revealed a decreased mortality rate associated with metformin use in diabetic patients with mild to moderate COVID-19 infection.3. This study suggests that diabetic patients may continue metformin treatment during a COVID-19 infection as the medication has sustained therapeutic effects. Abstract COVID-19 patients with comorbidities, such as type 2 diabetes (T2DM), have a higher mortality rate compared to those without any comorbidities. T2DM patients usually receive metformin as their first-line treatment. However, the effectiveness of metformin in reducing mortality rates still requires further analysis. The objective of this study was to analyze the effectiveness of metformin in reducing mortality rates among COVID-19 patients with T2DM. An analytic observational design with a retrospective cohort approach was used in this study. Samples were acquired from hospitalized COVID-19 patients with T2DM medical records at Fatmawati Central General Hospital, Jakarta, Indonesia, throughout 2020–2021. The samples were collected using a purposive sampling technique and analyzed using Chi-square test (p&lt;0.05; RR&lt;1). This study comprised 137 samples, with 56 samples receiving metformin and 81 not receiving metformin. The mortality rate in the sample group that received metformin was lower (19.6%) compared to the group that was not given the medication (38.3%). The Chi-square test results indicated a statistically significant relationship between metformin treatment and a lower mortality rate among COVID-19-contracted individuals with T2DM (p=0.020; RR=0.513). Therefore, this study concludes that the administration of metformin treatment reduces mortality among COVID-19 patients with T2DM.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2023-09-10</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v59i3.46944</dc:identifier><dc:identifier>10.20473/fmi.v59i3.46944</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 59 No 3 (2023); 267-273</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/46944/27185</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>